Navigation Links
Arena Pharmaceuticals Announces Positive Lorcaserin Pivotal Phase 3 Obesity Trial Results: Meets All Primary Efficacy and Safety Endpoints
Date:3/30/2009

ition. The trial did not include any dose titration or run-in period. Patients were randomized in a 1:1 ratio to lorcaserin or placebo at baseline. At Week 52, 856 patients taking lorcaserin were re-randomized in a 2:1 ratio to continue lorcaserin or to switch to placebo, and 697 patients on placebo were continued on placebo. Patients received echocardiograms at screening, and at 6, 12, 18 and 24 months after initiating dosing in the trial; patients with FDA-defined valvulopathy were excluded from enrolling in the trial.

Phase 3 Program Overview

The Phase 3 program consists of three trials, BLOOM, BLOSSOM and BLOOM-DM (Behavioral modification and Lorcaserin for Overweight and Obesity Management in Diabetes Mellitus), and is planned to enroll a total of approximately 7,800 patients. BLOOM and BLOSSOM comprise the Phase 3 pivotal registration program. BLOSSOM has enrolled 4,008 patients and is evaluating 10 mg of lorcaserin dosed once or twice daily versus placebo over a one-year treatment period in obese patients with or without co-morbid conditions and overweight patients with at least one co-morbid condition at about 100 sites in the US. Results are expected around the end of September 2009. BLOOM-DM is currently enrolling and is evaluating 10 mg of lorcaserin dosed once or twice daily versus placebo over a one-year treatment period in obese and overweight patients with type 2 diabetes at about 60 sites in the US. Approximately 600 patients are expected to be enrolled in BLOOM-DM, which is planned as a supplement to the lorcaserin NDA.

A standardized program of moderate diet and exercise guidance is included in the Phase 3 program. The program's hierarchically ordered co-primary efficacy endpoints are: the proportion of patients achieving 5% or greater weight loss after 12 months, the difference in mean weight loss compared to placebo after 12 months, and the proportion of patients achieving
'/>"/>

SOURCE Arena Pharmaceuticals, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9 10 11

Related medicine news :

1. Arena Pharmaceuticals to Present at the NewsMakers in the Biotech Industry Conference
2. Arena Pharmaceuticals Announces Public Offering of Common Stock
3. Arena Pharmaceuticals to Present at the BIOCOM Investor Conference
4. Arena Pharmaceuticals Announces Pricing of Public Offering of Common Stock
5. Arena Pharmaceuticals to Present at the Merrill Lynch Global Pharmaceutical, Biotechnology and Medical Device Conference
6. Arena Pharmaceuticals Lorcaserin for Obesity Passes Major Safety Milestone
7. Arena Pharmaceuticals to Present at the Morgan Stanley Global Healthcare Unplugged Conference
8. Arena Pharmaceuticals to Report First Quarter 2008 Financial Results and to Host Conference Call and Webcast on Wednesday, May 7, 2008
9. Field Poll: California Nurses Association Most Favorably Viewed Group in Healthcare Arena
10. Childrens Miracle Network and Arena Football League Partner for First Nationwide Celebration Event
11. Arena Pharmaceuticals Announces Third Quarter 2008 Financial Results
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/22/2015)... The American College of Traditional Chinese ... They will hold a webinar on the updates of ... on Classical Chinese Medicine. , Webinar – First Professional ... the Dean of Clinical Education, will lead this webinar ... Doctorate program. ACTCM is currently developing this degree program ...
(Date:5/22/2015)... New York, New York (PRWEB) May 22, 2015 ... ( http://www.xareltolawsuit2015.com/ ) filed on behalf of individuals ... complications due to its use continue to move ... of Louisiana. According to a Pretrial Order dated ... governing the preservation of documents and electronically stored ...
(Date:5/22/2015)... 2015 Combination therapy, or polytherapy, ... chronic obstructive pulmonary disorder (COPD) as the dominant ... plc as well as Germany’s Boehringer Ingelheim compete ... But will market payers, clinicians and patients be ... to completely new ones? , In spite of ...
(Date:5/22/2015)... Family, friends, students, colleagues, mentors and fellow physicians ... D. Leffall, on Monday, May 18, with an 85th ... in the hospital’s Tower Auditorium. Leffall’s younger sister, 83-year-old ... to keep the secret. “I’d like to go in ... know something is up,” she said. , After more ...
(Date:5/22/2015)... Memorial Day weekend is typically considered the beginning of vacation ... to help promote safe travel. , According to estimates from ... this Memorial Day weekend. Amica is sharing the following road ... , , Always wear a seatbelt: Make ... they’re driving or riding along as a passenger. Seatbelts are ...
Breaking Medicine News(10 mins):Health News:ACTCM Announces Upcoming June Events 2Health News:Court Overseeing Federal Xarelto Lawsuits Establishes Procedures Governing Preservation of Documents, Electronically Stored Information 2Health News:Court Overseeing Federal Xarelto Lawsuits Establishes Procedures Governing Preservation of Documents, Electronically Stored Information 3Health News:Court Overseeing Federal Xarelto Lawsuits Establishes Procedures Governing Preservation of Documents, Electronically Stored Information 4Health News:Chronic Obstructive Pulmonary Disorder Therapeutics Market Discussed in In-demand FirstWord Report Published at MarketPublishers.com 2Health News:Colleagues Surprise Dr. LaSalle Leffall with 85th Birthday Celebration 2Health News:Amica Has 4 Road Safety Tips for Memorial Day Weekend 2
... , MONDAY, Nov. 22 (HealthDay News) -- Infants with ... at high risk for heart and lung disorders that increase their ... analyzed the medical records of more than 50,000 very low birth ... at birth. They found that among this group of babies, those ...
... current staging system that determines the extent or severity ... online in CANCER , a peer-reviewed journal of ... is no link between localized prostate cancer,s clinical stage ... his prostate removed. One of the primary purposes ...
... discovered 30 new genes that control the age of ... also act on body weight regulation or biological pathways ... Nature Genetics , was a collaborative effort by ... 104 worldwide institutions, including Boston University School of Medicine ...
... African Americans with kidney disease related to hypertension (high ... a sharply increased risk of progressive kidney disease, according ... Nephrology,s 43rd Annual Meeting and Scientific Exposition. End Stage ... African American population at a rate 13.1 times greater ...
... Kidneys ,Kidney Donations by the Poor Are on the ... low incomes are more likely to develop kidney failure and ... people of other socioeconomic classes. Because fewer individuals in the ... University of British Columbia, in Vancouver, Canada) and colleagues examined ...
... in Fruits and Vegetables ,Healthy Foods Can Help Maintain ... disease, the Western diet produces an acidic environment in the ... as kidney function declines. Nimirit Goraya, MD (Texas A&M College ... conducted a study to see if consuming a diet high ...
Cached Medicine News:Health News:Tiniest Newborns With Down Syndrome Face Other Health Risks 2Health News:Genes link puberty timing and body fat in women 2Health News:Gene linked to worsening kidney disease in African-Americans 2Health News:Efforts needed to address disparities in kidney transplantation 2Health News:Efforts needed to address disparities in kidney transplantation 3Health News:Efforts needed to address disparities in kidney transplantation 4Health News:Kidneys: Produce-rich diet improves long-term health, melatonin improves short-term health 2Health News:Kidneys: Produce-rich diet improves long-term health, melatonin improves short-term health 3
(Date:5/22/2015)... 22, 2015 The leading companies in ... global cardiac rhythm management device market dominate their ... Medtronic, St. Jude Medical, Boston Scientific and Asahi ... market segment. The healthcare market research publisher,s report, ... 2015 as a base year, providing forecasts for ...
(Date:5/22/2015)...  The U.S. Food and Drug Administration,s (FDA) ... biosimilar product approved in the United ... the contract manufacturing organization (CMO) industry, according to ... to the production of small-molecular drugs and lacks ... healthcare market research publisher,s report, Biopharmaceutical and ...
(Date:5/22/2015)... 2015  The Mesothelioma Victims Center is incredibly ... get the best possible compensation, and they are also ... rare cancer caused by exposure to asbestos or ... to treatment options such as a recent possible ... Victims Center anytime at 866-714-6466. http://MesotheliomaVictimsCenter.Com ...
Breaking Medicine Technology:Kalorama: Top Companies Dominate Cardiac Defibrillator Market 2Kalorama: Top Companies Dominate Cardiac Defibrillator Market 3Kalorama: Top Companies Dominate Cardiac Defibrillator Market 4Kalorama: First FDA-Approved Biosimilar Brings Hope for CMO Growth 2Kalorama: First FDA-Approved Biosimilar Brings Hope for CMO Growth 3Kalorama: First FDA-Approved Biosimilar Brings Hope for CMO Growth 4Mesothelioma Victims Center Calls Attention to a Recent Medical Article About a New Drug That Could Slow the Progression of Mesothelioma and Allow People to Live Longer 2Mesothelioma Victims Center Calls Attention to a Recent Medical Article About a New Drug That Could Slow the Progression of Mesothelioma and Allow People to Live Longer 3Mesothelioma Victims Center Calls Attention to a Recent Medical Article About a New Drug That Could Slow the Progression of Mesothelioma and Allow People to Live Longer 4Mesothelioma Victims Center Calls Attention to a Recent Medical Article About a New Drug That Could Slow the Progression of Mesothelioma and Allow People to Live Longer 5
Meter Trax Control is a whole blood quality control that can be used for glucose, hemoglobin and hematocrit testing on point of care instruments....
Lyphochek® Hemoglobin A1C Linearity Set is a human whole blood based product designed to verify linearity throughout the patient reportable range of hemoglobin A1C assays....
Liquichek Reticulocyte Control is a human whole blood based control designed to monitor manual and automated methods for counting reticulocytes. Assayed values are provided at three clinically signif...
Seroconversion and Antigen Panel Chart...
Medicine Products: